N
ALT icon

Nuveen’s Altimmune ALT Stock Holding History

Nuveen’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-467,400
Closed -$6K – 3174
2022
Q3 		$6K Buy
+467,400
New +$6.9M ﹤0.01% 3195

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nuveen's ALT Position: Q1 2026 in Review

Nuveen increased its Altimmune (ALT) stake by 88% in Q1 2026, buying an estimated $4.63M and bringing the position to 2,334,601 shares worth $7.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1728.

Nuveen first reported a position in ALT in Q2 2021 and has held it in 20 quarters since. The position peaked at $53.7M in Q4 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Nuveen held 2,334,601 shares of Altimmune worth $7.19M as of Q1 2026.
  • Nuveen bought 1,090,390 Altimmune shares in Q1 2026, an estimated $4.63M.
  • Altimmune made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1728 holding.
  • Nuveen first reported a position in Altimmune in Q2 2021 and has held it in 20 quarters since.
  • Nuveen's Altimmune position peaked at $53.7M in Q4 2022.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.